Jingsheng Cai, Shaoyi Chen, Zheng Liu, Haoran Li, Peiyu Wang, Fan Yang, Yun Li, Kezhong Chen, Ming Sun, Mantang Qiu
{"title":"为体内嵌合抗原受体疗法赋能的 RNA 技术和纳米载体。","authors":"Jingsheng Cai, Shaoyi Chen, Zheng Liu, Haoran Li, Peiyu Wang, Fan Yang, Yun Li, Kezhong Chen, Ming Sun, Mantang Qiu","doi":"10.1111/imm.13861","DOIUrl":null,"url":null,"abstract":"<p>The remarkable success of mRNA-based coronavirus 2019 (COVID-19) vaccines has propelled the advancement of nanomedicine, specifically in the realm of RNA technology and nanomaterial delivery systems. Notably, significant strides have been made in the development of RNA-based in vivo chimeric antigen receptor (CAR) therapy. In comparison to the conventional ex vivo CAR therapy, in vivo CAR therapy offers several benefits including simplified preparation, reduced costs, broad applicability and decreased potential for carcinogenic effects. This review summarises the RNA-based CAR constructs in in vivo CAR therapy, discusses the current applications of in vivo delivery vectors and outlines the immune cells edited with CAR molecules. We aim for the conveyed messages to contribute towards the advancement of in vivo CAR application.</p>","PeriodicalId":13508,"journal":{"name":"Immunology","volume":"173 4","pages":"634-653"},"PeriodicalIF":4.9000,"publicationDate":"2024-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/imm.13861","citationCount":"0","resultStr":"{\"title\":\"RNA technology and nanocarriers empowering in vivo chimeric antigen receptor therapy\",\"authors\":\"Jingsheng Cai, Shaoyi Chen, Zheng Liu, Haoran Li, Peiyu Wang, Fan Yang, Yun Li, Kezhong Chen, Ming Sun, Mantang Qiu\",\"doi\":\"10.1111/imm.13861\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>The remarkable success of mRNA-based coronavirus 2019 (COVID-19) vaccines has propelled the advancement of nanomedicine, specifically in the realm of RNA technology and nanomaterial delivery systems. Notably, significant strides have been made in the development of RNA-based in vivo chimeric antigen receptor (CAR) therapy. In comparison to the conventional ex vivo CAR therapy, in vivo CAR therapy offers several benefits including simplified preparation, reduced costs, broad applicability and decreased potential for carcinogenic effects. This review summarises the RNA-based CAR constructs in in vivo CAR therapy, discusses the current applications of in vivo delivery vectors and outlines the immune cells edited with CAR molecules. We aim for the conveyed messages to contribute towards the advancement of in vivo CAR application.</p>\",\"PeriodicalId\":13508,\"journal\":{\"name\":\"Immunology\",\"volume\":\"173 4\",\"pages\":\"634-653\"},\"PeriodicalIF\":4.9000,\"publicationDate\":\"2024-09-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1111/imm.13861\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Immunology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/imm.13861\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Immunology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/imm.13861","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
基于 mRNA 的冠状病毒 2019（COVID-19）疫苗取得了巨大成功，推动了纳米医学的发展，特别是在 RNA 技术和纳米材料递送系统领域。值得注意的是，基于 RNA 的体内嵌合抗原受体（CAR）疗法的开发取得了重大进展。与传统的体外 CAR 疗法相比，体内 CAR 疗法具有多种优势，包括准备工作简化、成本降低、适用性广以及致癌作用的可能性降低。本综述总结了体内 CAR 疗法中基于 RNA 的 CAR 构建，讨论了体内递送载体的当前应用，并概述了使用 CAR 分子编辑的免疫细胞。我们希望所传达的信息能为推进体内 CAR 应用做出贡献。
RNA technology and nanocarriers empowering in vivo chimeric antigen receptor therapy
The remarkable success of mRNA-based coronavirus 2019 (COVID-19) vaccines has propelled the advancement of nanomedicine, specifically in the realm of RNA technology and nanomaterial delivery systems. Notably, significant strides have been made in the development of RNA-based in vivo chimeric antigen receptor (CAR) therapy. In comparison to the conventional ex vivo CAR therapy, in vivo CAR therapy offers several benefits including simplified preparation, reduced costs, broad applicability and decreased potential for carcinogenic effects. This review summarises the RNA-based CAR constructs in in vivo CAR therapy, discusses the current applications of in vivo delivery vectors and outlines the immune cells edited with CAR molecules. We aim for the conveyed messages to contribute towards the advancement of in vivo CAR application.
期刊介绍：
Immunology is one of the longest-established immunology journals and is recognised as one of the leading journals in its field. We have global representation in authors, editors and reviewers.
Immunology publishes papers describing original findings in all areas of cellular and molecular immunology. High-quality original articles describing mechanistic insights into fundamental aspects of the immune system are welcome. Topics of interest to the journal include: immune cell development, cancer immunology, systems immunology/omics and informatics, inflammation, immunometabolism, immunology of infection, microbiota and immunity, mucosal immunology, and neuroimmunology.
The journal also publishes commissioned review articles on subjects of topical interest to immunologists, and commissions in-depth review series: themed sets of review articles which take a 360° view of select topics at the heart of immunological research.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
